TAKEDA PHARMACEUTICAL CO LTD
TKPHFDrugs in Pipeline
131
Phase 3 Programs
90
Upcoming Catalysts
10
Next Catalyst
This month
Market Overview
Stock performance and key metrics
10 upcoming, 0 past
Trelagliptin 25 mg
Type 2 Diabetes Mellitus
TVP-1012 1mg
Parkinson's Disease
Vedolizumab SC
Colitis, Ulcerative
Lapaquistat acetate
Hypercholesterolemia
TAK-788
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
TAP-144-SR(6M)
Premenopausal Breast Cancer
TAK-755
Thrombotic Thrombocytopenic Purpura (TTP)
Teduglutide
Short Bowel Syndrome
Epoetin Alfa
Myelodysplastic Syndrome
Mezagitamab
Kidney Disease
Tetravalent Dengue Vaccine (TDV)
Dengue Fever
Pioglitazone and metformin
Diabetes Mellitus
TAK-881
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Allopurinol
Gout
omega-3-acid ethyl esters 90 (TAK-085)
Hypertriglyceridemia
TAK-625
Progressive Familial Intrahepatic Cholestasis (PFIC)
TAK-861
Narcolepsy Type 1
Lanadelumab
Hereditary Angioedema (HAE)
TAK-019
Coronavirus Disease (COVID-19)
Valsartan
Hypertension
Elritercept
Myelodysplastic Syndromes
Azilsartan medoxomil with or without add-on chlorthalidone
Hypertension
Glimepiride
Diabetes Mellitus, Type 2
rozerem
Insomnia
Cohort 1: Lubiprostone Capsule, Fasted
Healthy Volunteers
Vonicog alfa
Von Willebrand Disease
Pioglitazone and Glimepiride
Diabetes Mellitus
trifluridine/tipiracil
Metastatic Oesogastric Adenocarcinoma
High Dose Colchicine (4.8 mg total dose)
Gout
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction
Multiple Myeloma
Parathyroid hormone
Disruption or Dehiscence of Closure of Sternum or Sternotomy
Amoxicillin
H. Pylori Infection
Pevonedistat
Myelodysplastic Syndrome
Epoetin alfa or Epoetin beta
Chronic Renal Failure
SHP615
Nervous System Diseases
Lapaquistat acetate and simvastatin
Hypercholesterolemia
Low-dose rtPA
Ischemic Stroke
Magnesium Pantoprazole
GERD
FEIBA
Hemophilia A
Alogliptin and glimepiride
Type 2 Diabetes Mellitus
Olmesartan medoxomil-hydrochlorothiazide
Essential Hypertension
PEGylated Recombinant Factor VIII
Hemophilia A
Ponatinib
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Relugolix
Uterine Fibroids
Apremilast
Plaque Psoriasis
Glimepiride and Metformin
Diabetes Mellitus
Bismuth-Containing Quadruple Therapy
Gastric Ulcer
Azilsartan medoxomil and hydrochlorothiazide
Essential Hypertension
Vedolizumab IV
Ulcerative Colitis
Vortioxetine
Depressive Disorder, Major
TAK-438
Duodenal Ulcer
Lansoprazole
Gastric Ulcers
Alogliptin
Type 2 Diabetes Mellitus
Vedolizumab
Ulcerative Colitis
Zasocitinib
Plaque Psoriasis
Febuxostat
Hyperuricosuria
Ramelteon
Chronic Insomnia
TDV
Healthy Volunteers
Lubiprostone
Chronic Idiopathic Constipation
Febuxostat IR
Gout
Lapaquistat acetate and atorvastatin
Dyslipidemia
TAK-360
Narcolepsy Type 2
Vonoprazan
Helicobacter Pylori
Alogliptin and insulin
Diabetes Mellitus
Alogliptin and metformin
Diabetes Mellitus
ciclesonide (XRP1526)
Respiratory Tract Diseases
Alogliptin 25 mg
Diabetes Mellitus
IGI, 10%
Multiple Myeloma
Soticlestat
15q Duplication Syndrome
Alogliptin and voglibose
Type 2 Diabetes Mellitus
SYR-472
Type 2 Diabetes Mellitus
Dexlansoprazole MR
Esophagitis, Reflux
Dexlansoprazole
Gastroesophageal Reflux Disease (GERD)
TAK-771
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Fazirsiran Injection
Alpha1-Antitrypsin Deficiency
Ixazomib
Multiple Myeloma
Maribavir
Cytomegalovirus (CMV)
Azilsartan medoxomil
Hypertension
TAK-279
Ulcerative Colitis
Azilsartan medoxomil and chlorthalidone
Safety
Chlorthalidone
Hypertension
Actovegin
Post-Stroke Cognitive Impairment (PSCI)
Peginesatide
Anemia
Darvadstrocel
Complex Perianal Fistulas in Adult Participants With Crohn's Disease
Azilsartan
Pediatric Hypertension
HYQVIA
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
rVWF
Von Willebrand Disease (VWD)
TAK-928
IO-resistant sqNSCLC
TAK-875
Diabetes Mellitus
Alogliptin and pioglitazone
Type 2 Diabetes Mellitus
NoV GI.1/GII.4 Bivalent VLP Vaccine
Healthy Volunteers
B-MAD chemotherapy
Extranodal NK/T-cell Lymphoma
TAK-935
Epilepsy
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Colorectal Carcinoma
FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Colon Cancer
Colchicine, 0.6 mg PO BID
Atrial Fibrillation
Ondansetron
Nausea
Niraparib
Ovarian Cancer
Ramelteon and gabapentin
Sleep Initiation and Maintenance Disorders
Ixazomib 1 MG
Human Immunodeficiency Virus (HIV)
Vedolizumab 300 MG Injection [Entyvio]
Immune Checkpoint Inhibitor-Related Colitis
Ixazomib Citrate
Myeloma
Adcetris-Levact
Clinical Efficacy
AMG 706
Advanced Gastrointestinal Stromal Tumor
Fruquintinib Combined With Chemotherapy
Metastatic Colorectal Cancer (CRC)
TAK-850
Influenza
TAK-079
Myasthenia Gravis
Brentuximab Vedotin
Hodgkin Disease
BAX 888
Hemophilia A
Immune Globulin Infusion (Human), 10% Solution
Hematologic Malignancies
Tak-228 & Tak-117
Triple Negative Breast Cancer
Voglibose
Diabetes Mellitus, Type 2
Rusfertide
Polycythemia Vera
HGT-1110
Metachromatic Leukodystrophy (MLD)
TAK-954
Diabetic Gastroparesis
Asparaginase
ALL, Childhood
TAK-442
Venous Thromboembolism
Namilumab
Plaque Psoriasis
Brigatinib
NSCLC
Luvadaxistat
Schizophrenia
TAK228
Ovarian Cancer
SHP655
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Idursulfase-IT
Hunter Syndrome
TAK-226
Myelodysplastic Syndromes
TAK-583
Diabetic Neuropathies
Alisertib
Acute Myeloid Leukemia
Melphalan
Multiple Myeloma
TAK-505
Malignant Solid Tumors
TAK-875 and Sitagliptin
Diabetes Mellitus, Type 2
TAK-385
Endometriosis
SHP611
Metachromatic Leukodystrophy (MLD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Trelagliptin 25 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
TVP-1012 1mg | Phase 3 | Parkinson's Disease | - | - |
Vedolizumab SC | Phase 3 | Colitis, Ulcerative | - | - |
Lapaquistat acetate | Phase 3 | Hypercholesterolemia | - | - |
TAK-788 | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | - | - |
TAP-144-SR(6M) | Phase 3 | Premenopausal Breast Cancer | - | - |
TAK-755 | Phase 3 | Thrombotic Thrombocytopenic Purpura (TTP) | - | - |
Teduglutide | Phase 3 | Short Bowel Syndrome | - | - |
Epoetin Alfa | Phase 3 | Myelodysplastic Syndrome | - | - |
Mezagitamab | Phase 3 | Kidney Disease | - | - |
Tetravalent Dengue Vaccine (TDV) | Phase 3 | Dengue Fever | - | - |
Pioglitazone and metformin | Phase 3 | Diabetes Mellitus | - | - |
TAK-881 | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | - | - |
Allopurinol | Phase 3 | Gout | - | - |
omega-3-acid ethyl esters 90 (TAK-085) | Phase 3 | Hypertriglyceridemia | - | - |
TAK-625 | Phase 3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | - | - |
TAK-861 | Phase 3 | Narcolepsy Type 1 | - | - |
Lanadelumab | Phase 3 | Hereditary Angioedema (HAE) | - | - |
TAK-019 | Phase 3 | Coronavirus Disease (COVID-19) | - | - |
Valsartan | Phase 3 | Hypertension | - | - |
Elritercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Azilsartan medoxomil with or without add-on chlorthalidone | Phase 3 | Hypertension | - | - |
Glimepiride | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
rozerem | Phase 3 | Insomnia | - | - |
Cohort 1: Lubiprostone Capsule, Fasted | Phase 3 | Healthy Volunteers | - | - |
Vonicog alfa | Phase 3 | Von Willebrand Disease | - | - |
Pioglitazone and Glimepiride | Phase 3 | Diabetes Mellitus | - | - |
trifluridine/tipiracil | Phase 3 | Metastatic Oesogastric Adenocarcinoma | - | - |
High Dose Colchicine (4.8 mg total dose) | Phase 3 | Gout | - | - |
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction | Phase 3 | Multiple Myeloma | - | - |
Parathyroid hormone | Phase 3 | Disruption or Dehiscence of Closure of Sternum or Sternotomy | - | - |
Amoxicillin | Phase 3 | H. Pylori Infection | - | - |
Pevonedistat | Phase 3 | Myelodysplastic Syndrome | - | - |
Epoetin alfa or Epoetin beta | Phase 3 | Chronic Renal Failure | - | - |
SHP615 | Phase 3 | Nervous System Diseases | - | - |
Lapaquistat acetate and simvastatin | Phase 3 | Hypercholesterolemia | - | - |
Low-dose rtPA | Phase 3 | Ischemic Stroke | - | - |
Magnesium Pantoprazole | Phase 3 | GERD | - | - |
FEIBA | Phase 3 | Hemophilia A | - | - |
Alogliptin and glimepiride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Olmesartan medoxomil-hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
PEGylated Recombinant Factor VIII | Phase 3 | Hemophilia A | - | - |
Ponatinib | Phase 3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | - | - |
Relugolix | Phase 3 | Uterine Fibroids | - | - |
Apremilast | Phase 3 | Plaque Psoriasis | - | - |
Glimepiride and Metformin | Phase 3 | Diabetes Mellitus | - | - |
Bismuth-Containing Quadruple Therapy | Phase 3 | Gastric Ulcer | - | - |
Azilsartan medoxomil and hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
Vedolizumab IV | Phase 3 | Ulcerative Colitis | - | - |
Vortioxetine | Phase 3 | Depressive Disorder, Major | - | - |
TAK-438 | Phase 3 | Duodenal Ulcer | - | - |
Lansoprazole | Phase 3 | Gastric Ulcers | - | - |
Alogliptin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Vedolizumab | Phase 3 | Ulcerative Colitis | - | - |
Zasocitinib | Phase 3 | Plaque Psoriasis | - | - |
Febuxostat | Phase 3 | Hyperuricosuria | - | - |
Ramelteon | Phase 3 | Chronic Insomnia | - | - |
TDV | Phase 3 | Healthy Volunteers | - | - |
Lubiprostone | Phase 3 | Chronic Idiopathic Constipation | - | - |
Febuxostat IR | Phase 3 | Gout | - | - |
Lapaquistat acetate and atorvastatin | Phase 3 | Dyslipidemia | - | - |
TAK-360 | Phase 3 | Narcolepsy Type 2 | - | - |
Vonoprazan | Phase 3 | Helicobacter Pylori | - | - |
Alogliptin and insulin | Phase 3 | Diabetes Mellitus | - | - |
Alogliptin and metformin | Phase 3 | Diabetes Mellitus | - | - |
ciclesonide (XRP1526) | Phase 3 | Respiratory Tract Diseases | - | - |
Alogliptin 25 mg | Phase 3 | Diabetes Mellitus | - | - |
IGI, 10% | Phase 3 | Multiple Myeloma | - | - |
Soticlestat | Phase 3 | 15q Duplication Syndrome | - | - |
Alogliptin and voglibose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
SYR-472 | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Dexlansoprazole MR | Phase 3 | Esophagitis, Reflux | - | - |
Dexlansoprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
TAK-771 | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | - | - |
Fazirsiran Injection | Phase 3 | Alpha1-Antitrypsin Deficiency | - | - |
Ixazomib | Phase 3 | Multiple Myeloma | - | - |
Maribavir | Phase 3 | Cytomegalovirus (CMV) | - | - |
Azilsartan medoxomil | Phase 3 | Hypertension | - | - |
TAK-279 | Phase 3 | Ulcerative Colitis | - | - |
Azilsartan medoxomil and chlorthalidone | Phase 3 | Safety | - | - |
Chlorthalidone | Phase 3 | Hypertension | - | - |
Actovegin | Phase 3 | Post-Stroke Cognitive Impairment (PSCI) | - | - |
Peginesatide | Phase 3 | Anemia | - | - |
Darvadstrocel | Phase 3 | Complex Perianal Fistulas in Adult Participants With Crohn's Disease | - | - |
Azilsartan | Phase 3 | Pediatric Hypertension | - | - |
HYQVIA | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | - | - |
rVWF | Phase 3 | Von Willebrand Disease (VWD) | - | - |
TAK-928 | Phase 3 | IO-resistant sqNSCLC | - | - |
TAK-875 | Phase 3 | Diabetes Mellitus | - | - |
Alogliptin and pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
NoV GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Healthy Volunteers | - | - |
B-MAD chemotherapy | Phase 2 | Extranodal NK/T-cell Lymphoma | - | - |
TAK-935 | Phase 2 | Epilepsy | - | - |
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Phase 2 | Colorectal Carcinoma | - | - |
FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Phase 2 | Colon Cancer | - | - |
Colchicine, 0.6 mg PO BID | Phase 2 | Atrial Fibrillation | - | - |
Ondansetron | Phase 2 | Nausea | - | - |
Niraparib | Phase 2 | Ovarian Cancer | - | - |
Ramelteon and gabapentin | Phase 2 | Sleep Initiation and Maintenance Disorders | - | - |
Ixazomib 1 MG | Phase 2 | Human Immunodeficiency Virus (HIV) | - | - |
Vedolizumab 300 MG Injection [Entyvio] | Phase 2 | Immune Checkpoint Inhibitor-Related Colitis | - | - |
Ixazomib Citrate | Phase 2 | Myeloma | - | - |
Adcetris-Levact | Phase 2 | Clinical Efficacy | - | - |
AMG 706 | Phase 2 | Advanced Gastrointestinal Stromal Tumor | - | - |
Fruquintinib Combined With Chemotherapy | Phase 2 | Metastatic Colorectal Cancer (CRC) | - | - |
TAK-850 | Phase 2 | Influenza | - | - |
TAK-079 | Phase 2 | Myasthenia Gravis | - | - |
Brentuximab Vedotin | Phase 2 | Hodgkin Disease | - | - |
BAX 888 | Phase 2 | Hemophilia A | - | - |
Immune Globulin Infusion (Human), 10% Solution | Phase 2 | Hematologic Malignancies | - | - |
Tak-228 & Tak-117 | Phase 2 | Triple Negative Breast Cancer | - | - |
Voglibose | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Rusfertide | Phase 2 | Polycythemia Vera | - | - |
HGT-1110 | Phase 2 | Metachromatic Leukodystrophy (MLD) | - | - |
TAK-954 | Phase 2 | Diabetic Gastroparesis | - | - |
Asparaginase | Phase 2 | ALL, Childhood | - | - |
TAK-442 | Phase 2 | Venous Thromboembolism | - | - |
Namilumab | Phase 2 | Plaque Psoriasis | - | - |
Brigatinib | Phase 2 | NSCLC | - | - |
Luvadaxistat | Phase 2 | Schizophrenia | - | - |
TAK228 | Phase 2 | Ovarian Cancer | - | - |
SHP655 | Phase 2 | Acquired Thrombotic Thrombocytopenic Purpura (aTTP) | - | - |
Idursulfase-IT | Phase 2 | Hunter Syndrome | - | - |
TAK-226 | Phase 2 | Myelodysplastic Syndromes | - | - |
TAK-583 | Phase 2 | Diabetic Neuropathies | - | - |
Alisertib | Phase 2 | Acute Myeloid Leukemia | - | - |
Melphalan | Phase 2 | Multiple Myeloma | - | - |
TAK-505 | Phase 2 | Malignant Solid Tumors | - | - |
TAK-875 and Sitagliptin | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
TAK-385 | Phase 2 | Endometriosis | - | - |
SHP611 | Phase 2 | Metachromatic Leukodystrophy (MLD) | - | - |
Healthy Volunteers
1 drug in this indication
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in TAKEDA PHARMACEUTICAL CO LTD's drug pipeline?→
CatalystAlert tracks 131 drug candidates in TAKEDA PHARMACEUTICAL CO LTD's (TKPHF) pipeline across Phase 3, Phase 2. Its lead program is Trelagliptin 25 mg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TAKEDA PHARMACEUTICAL CO LTD's next FDA catalyst?→
TAKEDA PHARMACEUTICAL CO LTD's (TKPHF) next tracked catalyst is a Phase 3 expected October 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TKPHF biotech catalysts?→
Add TKPHF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TAKEDA PHARMACEUTICAL CO LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.